SAFETY PROFILE OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR RO4607381/JTT-705: RESULTS FROM PHASE II TRIALS

被引：0
|
作者：
Buckley, B. [1 ]
Kallend, D. [2 ]
Stein, E. A. [3 ]
机构：
[1] Natl Univ Ireland Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
[3] Metab & Atherosclerosis Res Ctr, Cincinnati, OH USA
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2008年 / 9卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(08)70834-1
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 31 条
  • [1] THE CARDIOVASCULAR SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR, RO4607381/JTT-705: PHASE II FINDINGS
    Stroes, E. S.
    Kastelein, J. J.
    Kallend, D.
    Steiner, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 12 - 12
  • [2] Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR)
    Niesor, E. J.
    von der Marck, E.
    Brousse, M.
    Maugeais, C.
    [J]. ATHEROSCLEROSIS, 2008, 199 (01) : 231 - 231
  • [3] Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Stein, Evan A.
    Roth, Eli M.
    Rhyne, James M.
    Burgess, Tracy
    Kallend, David
    Robinson, Jennifer G.
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (04) : 480 - 488
  • [4] Cardiovascular safety of the cholesteryl ester transfer protein inhibitor R1658/JTT-705: Results from phase 2 trials
    Steiner, George
    Kastelein, John J.
    Kallend, David
    Stroes, Erik S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A333 - A333
  • [5] The efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705
    De Grooth, GJ
    Kastelein, JJP
    [J]. CIRCULATION, 2001, 104 (17) : 176 - 176
  • [6] JTT-705 -: Treatment of lipoprotein disorders cholesteryl ester transfer protein inhibitor
    Alegret, M
    Silvestre, JS
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2004, 29 (08) : 787 - 792
  • [7] Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
    de Grooth, GJ
    Kuivenhoven, JA
    Stalenhoef, AFH
    de Graaf, J
    Zwinderman, AH
    Posma, JL
    van Tol, A
    Kastelein, JJP
    [J]. CIRCULATION, 2002, 105 (18) : 2159 - 2165
  • [8] Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia
    Huang, ZP
    Inazu, A
    Nohara, A
    Higashikata, T
    Mabuchi, H
    [J]. CLINICAL SCIENCE, 2002, 103 (06) : 587 - 594
  • [9] Safety profile of the cholesteryl ester transfer protein inhibitor R1658/JTT-705 in patients with type II Hyperlipidemia or coronary heart disease
    Stein, Evan A.
    Kallend, David
    Buckley, Brendan
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A333 - A334
  • [10] Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
    Kulvenhoven, JA
    de Grooth, GJ
    Kawamura, H
    Klerkx, AH
    Wilhelm, F
    Kastelein, JJ
    [J]. CIRCULATION, 2004, 110 (17) : 144 - 144
1234